Company intelligence / Profile preview

Syntara Limited

Frenchs Forest/Sydney, New South Wales, Australiasyntaratx.com.au ↗
Ownership
Private
Employees
~200
Development stage
Phase 2
01

Overview

Syntara is a clinical-stage biotech developing small molecule drugs that inhibit key enzymes driving extracellular matrix dysfunction. Its lead candidate SNT‑5505 is in Phase 2 for myelofibrosis with positive interim data; additional programs target myelodysplastic syndrome, skin scarring/fibrosis, neuroinflammatory diseases like Parkinson’s disease, and organ fibrosis. The company has collaborations with academic groups and patient organizations such as Parkinson’s UK. It previously developed two commercial respiratory products for which it receives royalties.

Therapeutic areas
OncologyDermatologyOtherHematologyNeurology
Modalities
Small molecules
Industry
Biotech
02

Drug pipeline

8 assets

amsulostat

2

7 more assets in the full pipeline.

Request access →
03

Partnerships

Parkinson's UK for neuroinflammation/Parkinson's programUniversity of Western Australia & Prof Fiona Wood for scar prevention/modificationHeidelberg University for MDS & CMML studies

Beyond the preview

Go deeper on Syntara Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntara Limited.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call